- Lobbying
- shire AND pharmaceuticals
Lobbying Arrangements Results for 'Shire Pharmaceuticals'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Advocacy on biotechnology coverage, reimbursement issues, and Right To Try legislation |
Shire Pharmaceuticals
|
KING & SPALDING LLP | |||
Details -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Newbo... |
Shire Pharmaceuticals LLC
|
in-house lobbying | |||
Details S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act |
Shire Pharmaceuticals LLC
Biopharmaceuticals research and manufacturing; health products |
THE WATTS GROUP PLLC | |||
Details Coverage/reimbursement/rebates in Medicaid and Medicare Parts B/D, ACA implementation |
Shire Pharmaceuticals
|
Kym H. Kilbourne | |||
Details Education |
Shire Pharmaceuticals, Inc.
Pharmaceuticals |
Buchanan Ingersoll, P.C. | |||
Details HR 1548 Pathway for Biosimilars Act -- focus on orphan drug issues HR 1427 Promoting Innovation and Access to Life Saving Medicine Act -- focus on orphan drug issues |
Shire Pharmaceuticals
|
THE WERNER GROUP | |||
Details Medicare |
Shire Pharmaceuticals LLC
|
SIDLEY AUSTIN LLP | |||
Details H.R. 1628, American Healthcare Act of 2017. access to rare and orphan disease therapeutics; newborn screening for heritable disorders; issues impacting pharmaceutical development approval and reim... |
Shire Pharmaceuticals LLC
|
STANTON PARK GROUP | |||
Details Worked with congressional offices on issues regarding the challenges of developing products for rare diseases. Met with Congress regarding "21st Century Cures," including company proposal. Met wi... |
Shire Pharmaceuticals, Inc.
|
HOLLAND & KNIGHT LLP | |||
Details Life Sciences Investment Act; ESRD orphan drugs; health care reform implementation; DEA Quotas; Drug shortage; CMS issues; PDUFA; exclusivity periods |
SHIRE PHARMACEUTICALS, INC.
|
BUCHANAN INGERSOLL & ROONEY PC | |||
Details Policies related to H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; General education about FDA appro... |
Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine
|
Williams and Jensen, PLLC | |||
Details Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 25... |
Shire Pharmaceuticals LLC
|
THE NICKLES GROUP, LLC |